Search the Newsreel

Praxis (PRAX) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Marcio De'SouzaChief Financial Officer - Tim KellyPresident of Research and Development - Steve PetrouChief Operating Officer - Megan Sniecinski TAKEAWAYS Cash and …

Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 12-Month High - Here's Why

Praxis Precision Medicines (NASDAQ:PRAX) recently hit a new 52-week high of $382.97, driven by positive analyst sentiment, including maintained "Buy" ratings and high price targets from HC Wainwright and RBC. The company beat quarterly EPS expectations and is anticipated to have significant catalysts in …

Praxis Home Retail revises promoter reclassification disclosure

Equities Analysts Offer Predictions for PRAX Q3 Earnings

HC Wainwright has revised its Q3 2026 EPS estimate for Praxis Precision Medicines (NASDAQ:PRAX) to a loss of $3.86 per share, maintaining a "Buy" rating and a $1,201 price target, indicating expectations for profitability by Q4 2027. Several other analysts also weighed in on …

H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,201

H.C. Wainwright has reiterated its Buy rating for Praxis Precision Medicines (PRAX.US), maintaining a target price of $1,201. This indicates continued confidence from the firm in the company's future performance.

Praxis Home Ret Standalone June 2026 Net Sales at Rs 26.60 crore, up 13.18% Y-o-Y

Can Praxis Precision Medicines' (PRAX) Extended Cash Runway Offset Mounting Losses In Its CNS Pipeline Push?

Praxis Precision Medicines, Inc. (PRAX) stock price, news, quote and history

This page provides a comprehensive overview of Praxis Precision Medicines, Inc. (PRAX) stock, including its current price, historical data, key statistics, and company profile. It details the company's focus on developing therapies for CNS disorders and lists its pipeline of clinical-stage and preclinical drug …

Praxis Precision Medicines (PRAX) Wins FDA Breakthrough Tag As CNS Pipeline Advances

Praxis Precision Medicines (PRAX) has achieved a significant milestone with its investigational treatment Elsunersen receiving FDA Breakthrough Therapy designation, advancing its central nervous system pipeline. Despite this regulatory success and other late-stage assets, the company reported substantial net losses and no meaningful revenue in …

Praxis Home Retail reports standalone net loss of Rs 11.06 crore in the June 2026 quarter

Praxis Precision Medicines, Inc. Stock 12‑Month Price Target Raised to $620.95, Implies 95% Upside

Praxis Precision Medicines, Inc. (PRAX) has seen its average 12-month stock price target raised to $620.95 by 19 analysts, up from $604.83. This new target suggests a potential upside of approximately 95% from its recent closing price. The consensus analyst rating for PRAX remains …

Praxis Home Retail Q1FY27 loss narrows to ₹1,106.49 lakhs

Praxis Precision Medicines (NASDAQ:PRAX) Releases Quarterly Earnings Results, Beats Estimates By $0.80 EPS

Praxis Precision Medicines (NASDAQ: PRAX) holds $1.4B cash, advances NDAs

Praxis Precision Medicines reported a Q2 2026 net loss of $83.7 million and a first-half loss of $176.3 million, driven by increased R&D and G&A expenses to fund clinical programs and commercial preparation. Despite these losses, the company holds $1.4 billion in cash, cash …

Praxis Precision Medicines gains as investors refocus on late-stage CNS pipeline and upcoming FDA catalysts

Praxis Precision Medicines (NASDAQ:PRAX) Sets New 12-Month High Following Better-Than-Expected Earnings

Praxis Precision Medicines stock hits 52-week high at 366.7 USD

Praxis Precision Medicines Inc. (PRAX) has reached a new 52-week high of $366.70, reflecting a 557% one-year return and a market cap of $9.92 billion, despite an InvestingPro analysis suggesting it may be overvalued. The company recently reported a Q2 2026 loss of $2.87 …

Earnings Flash (PRAX) Praxis Precision Medicines Posts Q2 Loss $2.87 a Share, vs. FactSet Est of $3.64 Loss

Praxis Precision Medicines beats Q2 loss estimates; shares rise

Praxis Precision Medicines Inc. (NASDAQ:PRAX) reported a Q2 loss of $2.87 per share, outperforming analyst estimates. The company's shares rose 6.5% in premarket trading following the news, which also highlighted progress with FDA interactions for its drug candidates ulixacaltamide HCl and relutrigine, and a …

Q2 2026 Praxis Precision Medicines Inc Earnings Call Transcript

Praxis Precision Medicines (PRAX) Earnings Date and Reports 2026

Praxis Precision earnings on deck as commercialization nears

Praxis Precision Medicines Inc. is set to report second-quarter results, with investors focused on cash burn and commercial readiness as the company awaits two key FDA drug approval decisions. Analysts have a strong buy rating with significant upside potential. The company's cash runway and …

29 New Praxis Employees Get Stock Units, Four-Year Vesting

Praxis Precision Medicines (PRAX) announced the grant of restricted stock unit (RSU) awards covering 7,318 common shares to 29 new non-executive employees. These inducement grants, made under the 2024 Inducement Plan and Nasdaq Listing Rule 5635(c)(4), will vest in four equal annual installments, contingent …

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines, Inc. announced that its Compensation Committee granted restricted stock unit awards covering 7,318 shares to 29 new non-executive employees on August 3, 2026. These grants were made under the company's 2024 Inducement Plan as material inducements for employment, in accordance with …

Responsive Playbooks and the PRAX Inflection

This article analyzes Praxis Precision Medicines Inc. (NASDAQ: PRAX), highlighting weak near and mid-term sentiment that contrasts with a positive long-term outlook. The report identifies no clear price positioning signals and notes elevated downside risk. It also provides three AI-generated trading strategies—Position, Momentum Breakout, …

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Recommendation of "Moderate Buy" by Analysts

Praxis Precision Medicines (PRAX) Projected to Announce Earnings on Monday

Praxis Precision Medicines Inc (PRAX) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Praxis Precision Medicines Inc (PRAX), which currently holds a financial score of 6.42, ranking 245 out of 384 in the Biotechnology & Medical Research industry. The company's financial status is stable with low operating efficiency. Key financial …

Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Praxis Precision Medicines, Inc. announced it will release its second-quarter financial results for the period ended June 30, 2026, and provide a corporate update on Thursday, August 6, 2026, before market open. The company will host a conference call and live webcast at 8:30 …

Praxis will webcast its second-quarter update Aug. 6 at 8:30 a.m.

Praxis Precision Medicines (NASDAQ: PRAX) announced it will report its Q2 2026 financial results and provide a corporate update on Thursday, August 6, 2026, before markets open. The company will host a conference call and live webcast at 8:30 a.m. ET on the same …

Praxis Precision Medicines Inc (PRAX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Praxis Precision Medicines Inc (PRAX), noting its current risk score of 2.04, which ranks it 242 out of 384 in the Biotechnology & Medical Research industry. The company's beta value of 2.75 indicates higher volatility compared to …

PRAX Reiterated by BTIG -- Price Target Maintained at $810

BTIG analyst Kambiz Yazdi reiterated a "Buy" rating for Praxis Precision Medicine (PRAX) and maintained an $810 price target despite the stock showing significant overvaluation at a 1114.8% premium to its GF Value™. The stock's GF Score™ of 38/100 highlights concerns in profitability and …

PRAX|Praxis Precision Medicines Inc|Price:293.038|Chg%:-2.772

This article provides a comprehensive stock analysis of Praxis Precision Medicines Inc (PRAX), highlighting its relatively healthy fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. Despite a recent weak stock market performance, the company shows strong fundamentals and …